IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 381 filers reported holding IONIS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,328,627 | +127.5% | 139,520 | +105.8% | 0.02% | +77.8% |
| Q2 2023 | $2,782,203 | -31.4% | 67,809 | -40.2% | 0.01% | -47.1% |
| Q1 2023 | $4,052,916 | -40.7% | 113,400 | -37.4% | 0.02% | -37.0% |
| Q4 2022 | $6,836,634 | +67.9% | 181,007 | +96.6% | 0.03% | +28.6% |
| Q3 2022 | $4,072,000 | -15.3% | 92,054 | -29.2% | 0.02% | -22.2% |
| Q2 2022 | $4,810,000 | +587.1% | 129,940 | +587.7% | 0.03% | +800.0% |
| Q1 2022 | $700,000 | -62.5% | 18,894 | -69.2% | 0.00% | -40.0% |
| Q4 2021 | $1,867,000 | -67.2% | 61,340 | -63.9% | 0.01% | -68.8% |
| Q3 2021 | $5,697,000 | +199.1% | 169,865 | +255.8% | 0.02% | +128.6% |
| Q2 2021 | $1,905,000 | +116.2% | 47,745 | +143.8% | 0.01% | +40.0% |
| Q1 2021 | $881,000 | -84.9% | 19,587 | -81.1% | 0.01% | -88.6% |
| Q4 2020 | $5,851,000 | +79.8% | 103,490 | +50.9% | 0.04% | 0.0% |
| Q3 2020 | $3,255,000 | +408.6% | 68,594 | +531.9% | 0.04% | +340.0% |
| Q2 2020 | $640,000 | -90.9% | 10,855 | -92.7% | 0.01% | -94.4% |
| Q1 2020 | $7,004,000 | -1.6% | 148,144 | +25.7% | 0.18% | +326.2% |
| Q4 2019 | $7,121,000 | -20.9% | 117,872 | -21.6% | 0.04% | -47.5% |
| Q3 2019 | $9,006,000 | -13.5% | 150,331 | -7.2% | 0.08% | -20.8% |
| Q2 2019 | $10,406,000 | +6.7% | 161,918 | +34.7% | 0.10% | -1.9% |
| Q1 2019 | $9,755,000 | +1581.9% | 120,180 | +1021.1% | 0.10% | +1371.4% |
| Q4 2018 | $580,000 | -88.3% | 10,720 | -89.1% | 0.01% | -91.9% |
| Q4 2017 | $4,960,000 | +476.7% | 98,617 | +481.4% | 0.09% | +405.9% |
| Q3 2017 | $860,000 | +290.9% | 16,962 | +291.9% | 0.02% | +325.0% |
| Q2 2017 | $220,000 | +9.5% | 4,328 | -13.4% | 0.00% | -33.3% |
| Q1 2017 | $201,000 | -40.4% | 5,000 | -45.7% | 0.01% | -72.7% |
| Q3 2016 | $337,000 | -34.4% | 9,200 | -27.6% | 0.02% | -45.0% |
| Q1 2016 | $514,000 | -13.6% | 12,700 | +32.3% | 0.04% | -38.5% |
| Q4 2015 | $595,000 | – | 9,600 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bellevue Group AG | 9,930,245 | $396,117,000 | 3.87% |
| Sicart Associates LLC | 368,409 | $14,696,000 | 3.50% |
| Camber Capital Management LP | 2,000,000 | $79,780,000 | 2.69% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 181,781 | $7,251,000 | 1.91% |
| SECTOR GAMMA AS | 263,488 | $10,511,000 | 1.86% |
| Parkman Healthcare Partners LLC | 136,380 | $5,440,000 | 1.19% |
| Eversept Partners, LP | 442,000 | $17,631,380 | 1.18% |
| Affinity Asset Advisors, LLC | 75,000 | $2,992,000 | 1.07% |
| TANAKA CAPITAL MANAGEMENT INC | 16,661 | $665,000 | 0.90% |
| Sonora Investment Management, LLC | 168,665 | $6,728,000 | 0.88% |